Clinical Support Services for the NIAMS Intramural Research Program

NIAMS 校内研究项目的临床支持服务

基本信息

批准号：
10023092
负责人：
Robert Colbert
金额：
$ 833.8万
依托单位：
NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES
依托单位国家：
美国
项目类别：
财政年份：
资助国家：
美国
起止时间：
至
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10023092
关键词：
Adult-Onset Still&apos s Disease Agonist Ambulatory Care Facilities Ankylosing spondylitis Appointments and Schedules Arthritis Behcet Syndrome Blood Blood Component Removal Blood Vessels Clinical Clinical Protocols Clinical Research Clinical Trials Collection Contracts Cross-Sectional Studies Databases Dermatomyositis Disease Double-Blind Method Enrollment Fellowship Frequencies Functional disorder Genetic Genetic Determinism Hospitalists IgG1 Inflammatory Infrastructure Institutional Review Boards Intramural Research Program Investigation Janus kinase Juvenile-Onset Still&apos s Disease Longitudinal Studies Lupus Medical Medicare Melorheostosis Molecular Monoclonal Antibodies National Institute of Arthritis and Musculoskeletal and Skin Diseases Natural History Neighborhood Health Center Neonatal Onset Multisystem Inflammatory Disease Nurse Practitioners Nursing Research Oral Orthopedic Procedures Outcome PPAR gamma Pathogenesis Patients Peroxisome Proliferator-Activated Receptors Phase Physicians Polymyositis Preparation Prevention Protocols documentation Randomized Research Activity Research Assistant Research Infrastructure Research Support Rheumatism Rheumatoid Arthritis Rheumatology Role Safety Services Severities Specimen Spinal Fusion Spondylarthritis Syndrome Systemic Lupus Erythematosus TNF gene Training Programs Translational Research Travel Treatment Protocols Undifferentiated United States National Institutes of Health Vasculitis autoinflammatory beneficiary congenital immunodeficiency cost double-blind placebo controlled trial healthy volunteer immunoregulation infliximab kinase inhibitor minority communities omalizumab open label placebo controlled study programs systemic autoimmunity systemic juvenile idiopathic arthritis

项目摘要

This project has provided research infrastructure support for the following clinical protocols: PEDIATRIC TRANSLATIONAL RESEARCH BRANCH 03-AR-0173 Studies of the Natural History, Pathogenesis and Outcome of (NOMID / CAPS, DIRA, CRMO, Still's Disease, Behcet's Disease, and other Undifferentiated Autoinflammatory Diseases) 11-AR-0223 Studies on the Natural History and Pathogenesis of Spondyloarthritis 12-AR-8001 Compassionate Use Treatment Protocol 14V-MC-JAGA Treatment of Autoinflammatory Syndromes Expected to Benefit from JAK 1/2 Inhibition 18-AR-0081: Investigation of the Natural History, Genetics and Pathophysiology of Systemic Juvenile Idiopathic Arthritis and Adult-onset Still's Disease and Related Inflammatory Conditions OFFICE OF THE CLINICAL DIRECTOR 91-AR-0196 Studies on the Natural History and Pathogenesis of Polymyositis, Dermatomyositis, and Related Diseases 94-AR-0066 Studies of the Pathogenesis and Natural History of Systemic Lupus Erythematosus (SLE) 00-AR-0222 Studies of the Pathogenesis and Natural History of Arthritis and Related Conditions 01-AR-0227 Natural History of Rheumatic Disease in Minority Communities 02-AR-0156 A Randomized, Double-Blind, Placebo-Controlled Trial of Infliximab In Patients With Dermatomyositis and Polymyositis 02-AR-0131 Collection Of Blood Components Using Apheresis From Patients With Rheumatic Diseases And Healthy Volunteers 13-AR-0005 A Phase 1b, Randomized, Double-Blind, Placebo Controlled Study with an Open Label Extension to Evaluate the Safety and Tolerability of Omalizumab, A Humanized IgG1 Monoclonal Antibody in Patients with Lupus (STOP LUPUS) 14-AR-0200: Studies of the Natural History, Pathogenesis and Outcome of Idiopathic Systemic Vasculitis 15-AR-0185: Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Systemic Lupus Erythematosus; a Phase Ib Clinical Trial and Associated Mechanistic Studies 15-AR-0165 Study of the Natural History, Pathogenesis and Outcome of Melorheostosis-a Rare Osteosclerotic Disease 07-AR-0146 Analysis of Stored Identified Specimens from Patients Enrolled in Protocol Number 98-AR-0150 AUTOIMMUNITY BRANCH 99-AR-0004 Molecular Basis of Primary Immunodeficiencies SYSTEMIC AUTOIMMUNITY BRANCH 15-AR-0060: The Role of PPAR-gamma Agonists in Immunomodulation and Vascular Prevention in SLE (PPAR-SLE). CLINICAL TRIALS AND OUTCOMES BRANCH 03-AR-0130 Genetic Determinants of Ankylosing Spondylitis Severity - Cross Sectional Study 03-AR-0131 Genetic Determinants of Ankylosing Spondylitis Severity - Longitudinal Study 03-AR-0133 Clinically Important Changes in Rheumatoid Arthritis 04-AR-0205 Progression of Spinal Fusion in Ankylosing Spondylitis 13-AR-0056: Stopping Anti-TNF Agents in Rheumatoid Arthritis (STARA) Trial 15-AR-N010: Frequency and Complications of Major Orthopedic Procedures in Medicare Beneficiaries

该项目为以下临床方案提供了研究基础设施支持：小儿翻译研究部门 03-AR-0173关于自然历史，发病机理和结果的研究（Nomid / Caps，Dira，Crmo，Still's Diseanty，Behcet病和其他未分化的自发性疾病） 11-AR-0223关于脊椎关节炎的自然病史和发病机理的研究 12-ar-8001同情使用治疗方案14V-MC-JAGA治疗自身炎症综合征的治疗，预计将受益于JAK 1/2抑制 20081年18月18日：全身少年特发性关节炎和成人疾病的自然史，遗传学和病理生理学的研究临床主任办公室 91-AR-0196关于多肌炎，皮肤炎和相关疾病的自然病史和发病机理的研究 94-AR-0066关于全身性红斑狼疮（SLE）的发病机理和自然历史的研究 00-AR-0222关于关节炎和相关疾病的发病机理和自然史的研究 01-AR-0227少数民族疾病的自然历史 02-ar-0156艾弗利昔单抗的一项随机，双盲，安慰剂对照试验对皮肌炎和多聚肌炎患者 02-ar-0131使用风湿病患者和健康志愿者的血液分泌收集血液成分 13-ar-0005 A期1B，随机，双盲，安慰剂对照研究，带有开放标签扩展，以评估狼疮患者中人源化的IgG1单克隆抗体（停止狼疮）的人性化IgG1单克隆抗体的安全性和耐受性 14-AR-0200：对特发性全身血管炎的自然病史，发病机理和结果的研究 0185年1月15日：在全身性红斑狼疮的口服Janus激酶抑制剂Tofacitinib的安全性； IB期临床试验和相关机理研究 15-AR-0165自然历史，发病机理和情绪疾病的结局研究 07-AR-0146分析已列出的已列出的标准标本的标本98-AR-0150 自身免疫分支原发性免疫缺陷的99-AR-0004分子基础系统性自身免疫分支 15-ar-0060：PPAR-GAMMA激动剂在SLE（PPAR-SLE）中的免疫调节和血管预防中的作用。临床试验和结果分支 03-AR-0130强直性脊柱炎严重程度的遗传决定因素 - 横截面研究 03-AR-0131强直性脊柱炎严重程度的遗传决定因素 - 纵向研究 03-AR-0133类风湿关节炎的临床上重要变化 04-AR-0205强直性脊柱炎中脊柱融合的进展 13-ar-0056：在类风湿关节炎（Stara）试验中停止抗TNF药物 15-AR-N010：Medicare受益人主要骨科手术的频率和并发症